ATI-1777|CAS 2321488-47-3|DC Chemicals

Cas No.:	2321488-47-3
Chemical Name:	Lepzacitinib
Synonyms:	GTPL12871;ATI1777;Ethyl (3R)-4-((1-(2-cyanoacetyl)piperidin-3-yl)amino)-1H-pyrrolo[2,3-b]pyridine-5-carboxylate;BDBM493018;ethyl 4-[[(3R)-1-(2-cyanoacetyl)piperidin-3-yl]amino]-1H-pyrrolo[2,3-b]pyridine-5-carboxylate;ethyl (R)-4-((1-(2-cyanoacetyl)piperidin-3-yl)amino)- 1H-pyrrolo[2,3-b]pyridine-5-carboxylate;DQN3V3R84U;HY-156621;Lepzacitinib;US10981906, Example 117;2321488-47-3;example 117 [WO2019090158A1];LEPZACITINIB [USAN];1H-Pyrrolo[2,3-b]pyridine-5-carboxylic acid, 4-[[(3R)-1-(2-cyanoacetyl)-3-piperidinyl]amino]-, ethyl ester;ATI-1777;SCHEMBL20990174;Ethyl 4-{[(3R)-1-(cyanoacetyl)piperidin-3-yl]amino}-1Hpyrrolo[ 2,3-b]pyridine-5-carboxylate;lepzacitinib [INN];CS-0886449
SMILES:	O=C(CC#N)N1CCC[C@H](C1)NC1C(C(=O)OCC)=CN=C2C=1C=CN2
Formula:	C₁₈H₂₁N₅O₃
M.Wt:	355.391043424606
Purity:	>98%
Sotrage:	2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO

MSDS

Cat. No.	Product name	Field of application
DC73569	Lepzacitinib (ATI-1777)	Lepzacitinib is a Janus kinase inhibitor targeting to JAK 1/3. Lepzacitinib exhibits anti-inflammatory effect and inhibits atopic dermatitis and other skin diseases.
DC72210	NDI-034858(Zasocitinib)	NDI034858 is a TYK2 inhibitor, target TYK2 JH2 domain with binding constant Kd of <200 pM.
DC72043	VVD-118313	VVD-118313 (compound 5a) is a potent, selective JAK1 inhibitor. VVD-118313 targets an isoform-restricted allosteric cysteine to block JAK1-dependent trans-phosphorylation and cytokine signaling. VVD-118313 can be used for research of cancer.
DC70831	TD-1473	TD-1473 (Izencitinib, TD1473, JNJ 8398) is a potent, selective, oral gut-selective pan-JAK inhibitor with pKi of 10.0/10.0/8.8/9.5 for human recombinant JAK1, JAK2, JAK3 and TYK2.TD-1473 inhibited cytokine-induced phosphorylation of STAT1 in mouse primary colonic epithelial cells with pIC50 values for inhibition against IL-6, IFNα and IFNγ were 7.3, 6.8 and 7.0.TD-1473 demonstrated JAK inhibitory activity in ex vivo mouse colon and human IBD patient colonic tissue. TD-1473 (Izencitinib) is under development for the treatment of ulcerative colitis.
DC70233	Londamocitinib（AZD4604）	AZD4604 (AZD-4604) is a potent, selective Janus-associated kinase 1 (JAK1) inhibitor with anti-inflammatory effect.
DC47591	JAK-IN-14	JAK-IN-14 is a potent and selective JAK1 inhibitor, with an IC50 of <5 μM. JAK-IN-14 is >8-fold more selective for JAK1 than JAK2 and JAK3 (Patent WO2016119700A1, compound 16).
DC47132	JAK1-IN-8	JAK1-IN-8, a potent JAK1 inhibitor (IC50<500 nM), compound 28, extracted from patent WO2016119700A1.
DC47066	Ifidancitinib	Ifidancitinib is a potent and selective inhibitor of JAK kinases 1/3. Ifidancitinib can be used in studies of allergies, asthma and autoimmune diseases.
DC47038	Fosifidancitinib	Fosifidancitinib is a potent and selective inhibitor of JAK kinases 1/3. Fociatinib is used in studies of allergies, asthma and autoimmune diseases.
DC47030	Ilunocitinib	Ilunocitinib (compound 27) is a JAK inhibitor (extracted from patent WO2009114512A1).

Lepzacitinib (ATI-1777)